Zacks Investment Research·10h ago
Vertex Posts Positive Phase II Data on Kidney Disease DrugVRTX announces positive AMPLIFIED data for inaxaplin, while completing AMPLITUDE enrollment and targeting interim results in early 2027.
Vertex's accelerating revenue growth, up 12.5% year-over-year to $3.3B in 2026Q2, is increasingly driven by new launches like Casgevy and VX-548, which may reduce historical concentration risk. Operating leverage has expanded margins to 37.4% while maintaining...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth accelerated to 12.5% year-over-year in 2026Q2, with gross margins resilient at 85.3% and operating margin expanding to 37.4% from 22.7% in 2025Q1, reflecting strong operating leverage.
Vertex invests in scientific innovation to create transformative medicines for serious diseases, focusing on discovering and developing innovative treatments.
Vertex was one of the first biotech firms to use rational drug design, establishing a strong reputation in the biopharmaceutical industry.
There is a bullish thesis on Vertex Pharmaceuticals, indicating positive investor sentiment and potential upside for the stock.
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 3, 2026 | $4.73-0.2% vs $4.74 | $3.3B+3.2% vs $3.2B |
Q2 2026 May 4, 2026 | $4.47+5.4% vs $4.24 | $3.0B-0.2% vs $3.0B |
Q1 2026 Feb 12, 2026 | $5.03-1.6% vs $5.11 | $3.2B+0.2% vs $3.2B |
Q4 2025 Nov 3, 2025 | $4.80+5.0% vs $4.57 | $3.1B+0.6% vs $3.1B |
VRTX announces positive AMPLIFIED data for inaxaplin, while completing AMPLITUDE enrollment and targeting interim results in early 2027.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Tuesday reported data from its Phase 2b AMPLIFIED trial evaluating inaxaplin in individuals with APOL1-mediated kidney disease (AMKD).
Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from the Phase 2b AMPLIFIED study of inaxaplin in people with APOL1-mediated kidney disease (AMKD) and modest proteinuria and in people with AMKD and type 2 diabetes. In this study, inaxaplin was evaluated as a 45 mg once-daily dose on top of optimized standard of care. Forty-one people were enrolled and dosed in two cohorts: 1) people with AMKD with modest proteinuria (UACR ≥0.1 g/g to.
Benchmark VRTX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Vertex Pharmaceuticals Incorporated (VRTX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $516.34 | $131.05B | 33.70 | 9.57% | 32.74% | 22.54% | — | |
| $801.82 | $82.61B | 19.33 | 0.99% | 27.86% | 18.49% | — | |
| $246.51 | $32.91B | 105.80 | 65.19% | 16.82% | 93.61% | — | |
| $62.21 | $12.02B | 34.56 | 12.87% | 2.14% | 1.18% | — | |
| $18.95 | $2B | -2.66 | 15.58% | -6.93% | -9.96% | — | |
| $14.88 | $1.47B | -2.55 | 20.13% | -81.79% | — | — |
Vertex Pharmaceuticals Incorporated (VRTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Vertex Pharmaceuticals Incorporated (VRTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 3, 2026·SEC
Jul 7, 2026·SEC
May 13, 2026·SEC
Get notified when VRTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Vertex Pharmaceuticals Incorporated (VRTX) stock FAQ — growth, dividends, profitability & financials explained
Vertex Pharmaceuticals Incorporated (VRTX) reported $12.62B in revenue for fiscal year 2025. This represents a 94820% increase from $13.3M in 1996.
Vertex Pharmaceuticals Incorporated (VRTX) grew revenue by 9.6% over the past year. This is steady growth.
Yes, Vertex Pharmaceuticals Incorporated (VRTX) is profitable, generating $4.41B in net income for fiscal year 2025 (32.7% net margin).
Vertex Pharmaceuticals Incorporated (VRTX) has a return on equity (ROE) of 22.5%. This is excellent, indicating efficient use of shareholder capital.
Vertex Pharmaceuticals Incorporated (VRTX) generated $3.80B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
